Specific Manifestations of Neurotoxicity of Some Drug Combinations for Treatment of Drug Resistant Tuberculosis from the Perspective of Experimental Studies

Specific Manifestations of Neurotoxicity of Some Drug Combinations for Treatment of Drug Resistant Tuberculosis from the Perspective of Experimental Studies

The objective: to evaluate comparative neurotoxicity of combinations of anti-tuberculosis and antimicrobial drugs with different and similar toxic potentials assessing behavioral changes in rats.Subjects and Methods: non-linear female rats divided in 3 groups were used in this study. For 14 days, th...

Full description

Bibliographic Details
Main Authors:	G. N. Mozhokina, A. G. Samoylova, I. A. Vasilyeva, I. A. Burmistrova
Format:	Article
Language:	Russian
Published:	New Terra Publishing House 2023-01-01
Series:	Туберкулез и болезни лёгких
Subjects:	drug-resistant tuberculosis antimycobacterial drugs adverse reactions neurotoxicity experiment behavioral reactions
Online Access:	https://www.tibl-journal.com/jour/article/view/1697

Similar Items

Possibilities of Using Nootropic Drugs to Reduce Neurotoxic Reactions Caused by Anti-tuberculosis Drugs in Experimental Conditions
by: G. N. Mozhokina, et al.
Published: (2024-07-01)

The problem of neurotoxicity of drugs in the treatment of tuberculosis patients
by: G. N. Mozhokina, et al.
Published: (2020-11-01)

Toxicity of treatment regimens for drugresistant tuberculosis.
by: G. N. Mozhokina, et al.
Published: (2022-03-01)

Variety of Adverse Reactions in Rats after Administration of Combination of Anti-tuberculosis and Antimicrobial Drugs with Different Safety Profiles
by: G. N. Mozhokina, et al.
Published: (2022-11-01)

Neurotoxic Side Effects of Antimicrobial and Anti-Tuberculosis Drugs
by: G. N. Mozhokina, et al.
Published: (2020-08-01)

The Use of Nootropic Drugs to Reduce Toxic Reactions in Rats to a Combination of Anti-Tuberculosis Drugs
by: G. N. Mozhokina, et al.
Published: (2024-12-01)

Specific Parameters of Toxic Reactions in Rats to the Combination of Delamanid and Drugs for Treatment of Drug Resistant Tuberculosis (A Pilot Study)
by: G. N. Mozhokina, et al.
Published: (2023-04-01)

Nephrotoxic characteristics of anti-tuberculosis drugs
by: G. N. Mozhokina, et al.
Published: (2019-11-01)

Adverse drug reaction patterns of first-line anti-tubercular drugs among saharia tuberculosis patients: An observational study in particularly vulnerable tribal group of Madhya Pradesh, India
by: Prashant Mishra, et al.
Published: (2023-01-01)

THE SAFETY AND EFFICACY OF RIFAPENTINE USED TO TREAT DRUG-SUSCEPTIBLE PULMONARY TUBERCULOSIS
by: N. V. Litvinova, et al.
Published: (2014-04-01)

EVALUATIONS OF ADVERSE DRUGS REACTIONS IN RUSSIA IN 2013
by: V. A. Merkulov, et al.
Published: (2022-05-01)

Parameters of hepatotoxic reactions caused by the combination of first line anti-tuberculosis drugs in rats with different acetylation phenotypes
by: G. N. Mozhokina, et al.
Published: (2020-08-01)

Incidence of adverse drug reactions among tuberculosis patients initiated on daily drug regimen in a southern district of Karnataka
by: R. N. Hithaish Kumar, et al.
Published: (2025-01-01)

Medications for Short-Course Chemotherapy of Drug Resistant Tuberculosis and Their Effect on the Host
by: G. N. Mozhokina, et al.
Published: (2022-09-01)

Drug resistance of <i>M. tuberculosis</i> (historical aspects, current level of knowledge)
by: I. A. Burmistrova, et al.
Published: (2020-02-01)

Pattern of Adverse Drug Reactions and Performed Monitoring Laboratory-Tests in Patients Receiving Anti Tuberculosis Treatment in an Endemic Region, Zabol
by: Mandana Moradi, et al.
Published: (2024-10-01)

Prospects for Adding Drugs with Known Anti-tuberculosis Activity to the Composition of Bone Cement for Treatment of Tuberculous Arthritis
by: E. O. Peretsmanas, et al.
Published: (2022-10-01)

Tolerability of Tuberculosis Chemotherapy in Children
by: M. E. Lozovskaya, et al.
Published: (2023-12-01)

Amplification of drug resistance against the background of inadequate chemotherapy for pulmonary tuberculosis
by: I. A. Burmistrova, et al.
Published: (2019-09-01)

Cutaneous Adverse Drug Reaction Among HIV-Infected Patients Starting Antituberculosis Treatment
by: Alvina Widhani, et al.
Published: (2022-12-01)

Clinical and pharmacological monitoring of drug safety in pediatrics
by: N. V. Verlan, et al.
Published: (2016-05-01)

Effect of Genetic Polymorphism of the Enzyme Genes Responsible for Biotransformation of Antituberculous Drug on the Risk of Hepatotoxic Reaction in Patients with Tuberculosis
by: A. V. Kazakov, et al.
Published: (2020-05-01)

Drug-Induced Neutropenia and Agranulocytosis
by: O. D. Ostroumova, et al.
Published: (2020-09-01)

FREQUENCY AND CHARACTERISTICS OF ADVERSE REACTIONS TO SECOND LINE ANTI-TUBERCULOSIS DRUGS IN THOSE ILL WITH MULTIPLE DRUG RESISTANT TUBERCULOSIS
by: A. A. Toktogonova
Published: (2017-11-01)

Safety of treatment regimens in multiple drug resistant tuberculosis patients compiled as per the new WHO recommendations as of 2019
by: D. A. Ivanova, et al.
Published: (2020-02-01)

Tolerability and Efficacy of Chemotherapy Containing Bedaquiline in Patients with Multiple Drug Resistant Pulmonary Tuberculosis
by: O. V. Filinyuk, et al.
Published: (2022-10-01)

Profile of adverse drug reaction reports in South Africa: An analysis of VigiBase® for the year 2017
by: H Steyn
Published: (2023-06-01)

Common Adverse drug reactions to First line drugs in Tuberculosis care and the role of m-Health in patient self-reporting and pharmacovigilance in Nigeria: A Narrative review
by: Edward E, et al.
Published: (2021-04-01)

MONITORING OF DRUG SAFETY IN CLINICAL PRACTICE
by: N. V. Verlan, et al.
Published: (2017-02-01)

Drug-induced parkinsonism
by: T. M. Ostroumova, et al.
Published: (2021-12-01)

Use of Dispersible Fixed-Dose Combinations in Chemotherapy of Drug Susceptible Tuberculosis: Results of the Observational Study
by: E. S. Nikitina, et al.
Published: (2024-10-01)

Drug Hypersensitivity Associated with Dental Treatments
by: Ricardo Dias de Castro, et al.
Published: (2024-05-01)

Evaluation of potential drug-drug interactions in hospitalized patients at a tertiary care hospital: A pilot study
by: Yesim Kaya Yasar, et al.
Published: (2020-06-01)

Adverse drug reactions following treatment of latent tuberculosis infection: a linked national tuberculosis surveillance with claims database
by: Yu-Seon Jung, et al.
Published: (2024-11-01)

Beta-lactam antibiotics as reserve medications for the treatment of drug-resistant tuberculosis
by: G. N. Mozhokina, et al.
Published: (2021-08-01)

Isoniazid-induced Tenosynovitis: A Rare Case Report
by: Piyush Kumar Jain, et al.
Published: (2024-12-01)

Tolerability of individual chemotherapy regimens in children suffering from respiratory tuberculosis and exposed to multiple and extensive drug resistant tuberculosis
by: M. F. Gubkinа, et al.
Published: (2021-04-01)

Rational Organisation of Adverse Drug Reaction Monitoring
by: L. V. Shukil, et al.
Published: (2022-10-01)

Changes of approaches to chemotherapy in children of the tender age over 30-year period
by: A. R. Аroyan, et al.
Published: (2018-11-01)

Delamanid: Safety and Efficacy Analysis
by: G. N. Mozhokina, et al.
Published: (2023-12-01)